Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

84.53 -0.46 (-0.55%)

Streaming Delayed Price Updated: 1:59 PM EST, Feb 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression ↗

April 24, 2023

Via Benzinga

Could This Rare-Disease Drug Candidate Become a Blockbuster? ↗

April 19, 2023

This drug candidate could be a great treatment option for patients with a potentially deadly disease.

Via The Motley Fool

Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward' ↗

April 12, 2023

SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy...

Via Benzinga

Analyst Expectations for Ionis Pharmaceuticals's Future ↗

April 11, 2023

Via Benzinga

AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review ↗

March 27, 2023

Via Benzinga

Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement ↗

March 23, 2023

The companies are focusing on a small population of ALS patients with a genetic mutation.

Via Investor's Business Daily

Analyst Ratings for Ionis Pharmaceuticals ↗

March 21, 2023

Via Benzinga

Ionis Pharmaceuticals's Earnings Outlook ↗

February 21, 2023

Via Benzinga

Analyst Expectations for Ionis Pharmaceuticals's Future ↗

January 19, 2023

Via Benzinga

The Latest Analyst Ratings for Ionis Pharmaceuticals ↗

December 21, 2022

Via Benzinga

FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder ↗

March 23, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 ↗

March 21, 2023

Via Benzinga

Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year ↗

March 16, 2023

Via Benzinga

Analyst Says Ionis' Additional Hereditary Angioedema Study Data Supports 'Highly Competitive Profile' ↗

February 21, 2023

Via Benzinga

Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

December 13, 2022

Via Benzinga

4 Analysts Have This to Say About Ionis Pharmaceuticals ↗

November 10, 2022

Analysts have provided the following ratings for Ionis Pharmaceuticals (NASDAQ:IONS) within the last quarter:

Via Benzinga

Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric ↗

February 02, 2023

The company that remains still has a large pipeline of non-migraine assets.

Via Investor's Business Daily

Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness

January 09, 2023

From Royalty Pharma plc

Via GlobeNewswire

Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies

January 04, 2023

From Biogen Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022 ↗

December 21, 2022

Via Benzinga

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗

November 16, 2022

Neurodegenerative disorders could mean big bucks for some biotechs.

Via Investor's Business Daily

Phillips 66 To Rally 25%? Here Are 5 Other Price Target Changes For Thursday ↗

November 10, 2022

Via Benzinga

Ionis Regains Rights To Thrombosis Candidate From Bayer ↗

November 04, 2022

Via Benzinga

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗

October 20, 2022

Despite enthusiasm in some camps, the risk of potential cures clouds market projections.

Via Investor's Business Daily

3 Biotech Stocks to Sell in October ↗

September 29, 2022

These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market.

Via InvestorPlace

Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test ↗

September 29, 2022

Patients didn't show any improvements in a study meant to test multiple drugs.

Via Investor's Business Daily

Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test ↗

September 23, 2022

Though successful in early testing, it wasn't enough to win a Phase 3 study.

Via Investor's Business Daily

AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med ↗

September 23, 2022

Via Benzinga

There's 'Outsized' Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30% ↗

September 09, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗

September 09, 2022

Upgrades

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.